128 related articles for article (PubMed ID: 38552822)
1. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
2. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
3. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
[TBL] [Abstract][Full Text] [Related]
5. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
[TBL] [Abstract][Full Text] [Related]
6. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Aquilante CL; Sheeder J; Guiahi M; Teal S
Contraception; 2019 Jul; 100(1):37-41. PubMed ID: 30980827
[TBL] [Abstract][Full Text] [Related]
7. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
8. Twelve-month Continuation of the Etonogestrel Implant in Adolescents With Polycystic Ovary Syndrome.
Buyers E; Sass AE; Severn CD; Pyle L; Cree-Green M
J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):33-39. PubMed ID: 32919086
[TBL] [Abstract][Full Text] [Related]
9. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
10. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial.
Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM
Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and continuation rates of the etonogestrel-subdermal contraceptive implant versus short-acting contraceptive methods offered at no cost in Campinas, Brazil.
Laporte M; Marcelino AC; da Cunha Pereira P; Espejo-Arce X; Juliato CT; Bahamondes L
Int J Gynaecol Obstet; 2024 Jul; 166(1):305-311. PubMed ID: 38328989
[TBL] [Abstract][Full Text] [Related]
12. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Davis A; Swartz M; Guiahi M
Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
[TBL] [Abstract][Full Text] [Related]
13. A UPLC-MS/MS method for therapeutic drug monitoring of etonogestrel.
Thomas T; Petrie K; Shim J; Abildskov KM; Westhoff CL; Cremers S
Ther Drug Monit; 2013 Dec; 35(6):844-8. PubMed ID: 24081205
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
Wenzl R; van Beek A; Schnabel P; Huber J
Contraception; 1998 Nov; 58(5):283-8. PubMed ID: 9883383
[TBL] [Abstract][Full Text] [Related]
15. Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.
Gertz AM; Bishop IJ; Simon B; Lechiile K; Badubi O; Mussa A; Westhoff CL; Morroni C
Contraception; 2020 Dec; 102(6):403-405. PubMed ID: 32858051
[TBL] [Abstract][Full Text] [Related]
16. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Dindinger E; Harrison M; Sheeder J; Teal S
Obstet Gynecol; 2019 Oct; 134(4):807-813. PubMed ID: 31503152
[TBL] [Abstract][Full Text] [Related]
17. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
[TBL] [Abstract][Full Text] [Related]
18. Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
Ferreira-Filho ES; Bahamondes L; Duarte DC; Guimarães ALM; de Almeida PG; Soares-Júnior JM; Baracat EC; Sorpreso ICE
Gynecol Endocrinol; 2022 Jan; 38(1):90-93. PubMed ID: 34486922
[TBL] [Abstract][Full Text] [Related]
19. A prospective pilot study to assess the impact of the etonogestrel implant on postpartum depression.
Ross CM; Hammond C; Ralph JA; Balmert LC; Wisner KL; Kiley JW
Eur J Contracept Reprod Health Care; 2021 Apr; 26(2):98-104. PubMed ID: 33164593
[TBL] [Abstract][Full Text] [Related]
20. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]